Purpose: in the various groups were determined by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting as appropriate. Results: The expressions of α-SMA, fibronectin, collagen І, TGF-β and smad2 were significantly upregulated in HPMCs by PDF treatment, but smad7 was down-regulated, relative to the control group (p < 0.01).These PDF-induced effects were reversed by T-IIA (p < 0.05). Inhibition of TGF-β/smad pathway by LY364947 treatment led to significant decrease in the expressions of fibrosis-related proteins, when compared with PDF group (p < 0.05). TGF-β treatment also produced numerous spindleshaped HPMCs characteristic of epithelial-mesenchymal transition (EMT). However, this morphological transition was alleviated, and the expression levels of EMT-related proteins were significantly downregulated by exposure to the two doses of T-IIA (p < 0.05). Conclusion: Tanshinone IIA inhibits EMT in HPMCs by regulating TGF-β/smad pathway, thus mitigating peritoneal fibrosis. Therefore, T-IIA has promising potential as a new drug for the treatment of peritoneal dialysis (PD)-induced fibrosis. This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest
INTRODUCTION
End-stage renal disease (ESRD) is a major public health issue all over the world [1] . Peritoneal dialysis (PD) is a widely used renal replacement treatments for ESRD. However, about 3 -36 % of PD patients have experienced peritoneal ultrafiltration failure within 1 -4 y after PD [2] . The major cause of peritoneal ultrafiltration failure is peritoneal fibrosis: repeated PD increases the risk of peritoneal fibrosis, resulting in peritoneal ultrafiltration failure which eventually forces patients to abandon the treatment [2, 3] . Therefore, peritoneal fibrosis is a critical constraint in the development of PD. Thus, it is important to investigate the mechanism of peritoneal fibrosis and develop new therapeutic targets for the disease as a way of enhancing the development of PD.
Peritoneal fibrosis is characterized by absence of peritoneal mesothelial cell layer and increase in mesenchymal layer [3, 4] . Factors such as peritoneal dialysis fluid biocompatibility, peritonitis, and cytokines are implicated in the etiology of peritoneal fibrosis [3, 4] . Multiple mechanisms contribute to the incidence and progression of the disease. These include fibrosis-promoting factor, oxidative stress and peritoneal EMT of mesothelial cells [3, 4] . However, EMT is the main mechanism involved in peritoneal fibrosis [4] .
EMT is a biological process in which mature epithelial cells are transformed into cells with mesenchymal phenotype [5] . During this process, epithelial cells usually lose their adhesion ability and rearrange their cytoskeleton, leading to a decline in peritoneal function [5] . It has been reported that many signal transduction pathways may lead to EMT in peritoneal mesothelial cells. These are ROS / MMP-9 pathway [6] , PI3k / AKT pathway [7] , and transforming growth factor (TGF-β) signaling pathway [8] . Accumulating evidence have consistently indicated that TGF-β1 is the marker that induces EMT in peritoneal mesothelial cells, and that the TGF-β1 / smad3 signaling pathway is a key factor involved in EMT [8] [9] [10] . Although a lot of studies have been carried out on peritoneal mesothelial cell EMT, the mechanisms involved in the process have not been fully elucidated. It has been reported that T-IIA, an active component of the Chinese herb Danshen, inhibits fibrosis in various tissues [11] [12] [13] . In previous animal studies, it was shown that T-IIA significantly inhibited high glucose-based, PDFinduced peritoneal fibrosis [14] . The present study was aimed at investigating the effects of T-IIA on PDF-induced expression of fibrogenic cytokines in cultured HPMCs, and the underlying mechanism(s).
EXPERIMENTAL

Chemicals and reagents
Tanshinone IIA ( Figure 1 ) was obtained from Carephar (Nanjing, China). Dianeal-n PD-4 with 4.25 % glucose (PDF) was obtained from Baxter (Guangzhou, China). All the antibodies were purchased from Abcam (USA). Normal Australian fetal bovine serum (FBS), high-glucose DMEM medium, and 0.25 % EDTA-Trypsin were purchased from GIBCO (NY, USA). Trizol reagent was product of Invitrogen (California, USA), and real-time PCR reaction kit was from Takara (Dalian, China). 
Cell culture
Human peritoneal mesothelial cells (HPMCs) were obtained from ATCC (VA, USA). The cells were cultured in a high-glucose DMEM medium containing 10 % FBS in a 5 % CO 2 humidified incubator at 37 °C. The third-generation cells were used for subsequent experiments. When grown to sub-fusion state, the cells were incubated in serum-free culture medium for 24 h to synchronize cell growth, and then assigned to 7 groups: the control group, PDF group, PDF+50 μM T-IIA group, PDF + 5 μM TGF-β inhibitor (LY364947) group, 5 ng/mL TGF-β group, 5 ng/mL TGF-β + 50 μM T -IIA group and 5 ng/mL TGF-β + 100 μM T -IIA group. The cells were then used for the following experiments after another 72 h culture in their respective treatment states.
Real-time quantitative PCR
Trizol reagent (Invitrogen, USA) was used to extract the total RNA from the cells, cDNA was synthesized using commercially available reverse transcription kit (Takara, China). RNA (1ug) was reverse-transcribed into cDNA, which was then subjected to PCR amplification. The PCR reactions were performed using ABI 7500 Real-Time PCR System (ABI, USA). The amplification conditions were as follows: 95 °C for 30 s; 95 °C for 5 s, 60 °C for 34 s (40 cycles). The gene specific primer pairs for TGF-β, smad2, smad7, α-SMA, fibronectin, collagen І, Ecadherin, N-cadherin, MMP-2, MMP-9, and GADPH are listed in Table 1 . All the mRNA expression levels were normalized to that of GADPH using the 2 ∆∆Ct method. All the determinations were conducted in triplicate.
Western blot analysis
The cells were harvested and lysed in RIPA buffer (Sigma-Aldrich, USA). BCA assay (Thermo Fisher Scientific, USA) was applied to determine the protein concentrations. Extracted total protein (30μg) was separated by 10 % SDS-PAGE, electro-transferred onto a polyvinylidene fluoride (PVDF) membrane, and sealed with skim milk at 4 o C overnight. Then, the membrane was incubated with primary antibodies (Abcam, USA) against TGF-β, smad2, smad7, α-SMA, fibronectin, collagen І, E-cadherin, N-cadherin, MMP-2, MMP-9, tubulin, and GADPH for 4 hours at room temperature. The membrane was washed 3 times with Tris-buffered saline containing 0.1 % Tween-20 (TBS-T), and incubated with horseradish peroxidase (HRP) conjugated to goat anti-mouse secondary antibody (1:2000; Abcam, USA) at room temperature for two hours. It was then washed thrice in TBS-T. Tubulin and β-actin were used as internal references. Bands were developed using an electro-chemiluminescence (ECL) kit (Thermo Fisher Scientific, USA).
Statistical analysis
Analyses were performed using SPSS v.13.0 (SPSS Inc., Chicago, IL). The results are presented as mean ± SD. Differences between groups were assessed by one-way ANOVA. Statistical significance was assumed at p < 0.05 (two-tailed).
RESULTS
T-IIA exerted protective effect against PDFinduced fibrosis in HPMCs
To study the effect of T-IIA on PDF-induced fibrosis, the expression levels of fibrosis-related proteins in HPMCs were determined. RT-PCR analysis (Figure 2 A) showed that the mRNA expression levels of α-SMA, fibronectin, and collagen І were significantly up-regulated in HPMCs when treated with PDF (p < 0.01, relative to the control group). Consistent with the mRNA expression, the protein expression levels of these proteins were also significantly upregulated when compared with the control group (p < 0.05; Figures 2B and Figure 2C ). Moreover, in the PDF+IIA group, T-IIA treatment significantly decreased the expressions of α-SMA, fibronectin, and collagen І with respect to mRNA ( Figure 2A ) and protein (Figures 2B and Figure 2C ). This indicates that T-IIA exerts protective effect on the HPMCS. Interestingly, PDF treatment significantly up-regulated the expressions of TGF-β and smad2, and downregulated the expression of smad7 (p < 0.01, relative to the control group; Figure 2) . These effects brought about by PDF were reversed by T-IIA treatment (p < 0.05, when compared to the PDF group; Figure 2) .
T-IIA treatment inhibited fibrosis in HPMCs by regulation of the TGF-β/smad pathway
As shown in Figure 3 , LY364947 treatment significantly inhibited the expression of TGF-β (p < 0.05, versus the PDF group), and downregulated the expressions of smad2, and smad7. Figure 3) .
T-IIA treatment inhibited EMT of HPMCs
Characteristically, mesenchymal cells have highly proliferative ability, with spindle-shape and well-spread morphology [15] . As shown in Figure  3A , TGF-β treatment led to appearance of numerous spindle-shaped HPMCs, which indicates that the HPMCs underwent EMT. However, this morphological transition was alleviated by exposure of the HPMCs to different concentrations of T-IIA. Moreover, RT-PCR ( Figure 4B ) and Western blot (Figures 4C and Figure 4D ) results showed that the expressions of N-cadherin, MMP-2, and MMP-9 were significantly decreased, compared with the TGFβ group, while E-cadherin expression was significantly up-regulated (p < 0.05). These results indicate that T-IIA treatment inhibited the EMT process induced in HPMCs by TGF-β.
DISCUSSION
Peritoneal dialysis (PD) is an important alternative treatment for ESRD. In PD, the peritoneum is used as a semipermeable membrane to remove metabolic wastes and excess water in the body according to dispersion and penetration principles [2, 3] . It has always been thought that the activation of fibroblasts inherent in peritoneal tissue and the infiltration of inflammatory cells are the most important factors that cause structural and functional changes in peritoneal tissue [16] . However, recent studies have found that the long-term stimulation by nonbiocompatible peritoneal dialysis solution can lead to the EMT of peritoneal mesothelial cells [2, 3, 16] . EMT is a highly regulated process that has a vital role in embryonic development, tumor formation and fibrosis in some chronic inflammatory diseases [3, 4] . Peritoneal mesothelial cell EMT is one of the key factors responsible for gradual decreases in peritoneal functions in peritoneal dialysis patients [3, 4] . TGF-β1 is an important fibrosis-promoting factor in several tissues and organs, including peritoneal tissue; its role is to phosphorylate the signaling protein smad2 /3 [17] . Smad protein is a downstream signal regulatory protein of the TGF-β1 receptor complex, and it transfers TGF-β signal from the cell membrane to the nucleus [17, 18] . Many of the biological function of TGF-β are mediated by smads signaling pathway, and smad2 / 3 falls into the type of receptormodulating smads, the phosphorylation of which acts as the most important step and sign of smad pathway activation [17, 18] . Therefore, the expression level of intracellular p-smad2 /3 is an index of the degree of activation of the pathway.
Excessive expression of smad7 inhibits the binding of smad2 and smad3 molecules to activated type I receptors as well as their phosphorylation, thereby exerting a negative regulating effect on TGF-β signal transduction [19] . Down-regulation of the expression of smad7 protein is associated with fibrosis, while the upregulation of its expression reverses the occurrence and progression of fibrosis [17, 19] . This is consistent with the results obtained in this study. PDF treatment significantly up-regulated the expression of TGF-β and smad2, and downregulated the expression of smad7, but this trend was reversed by T-IIA. This finding indicates that T-IIA inhibits fibrosis in HPMCs by regulation of the TGF-β/smad pathway.
TGF-β1 is also a key regulator of EMT [8] . It can induce transition in HPMCs in vitro and in vivo [20, 21] . The transition of epithelial cells to mesenchymal cells involves loosening of epithelial cells, loss of microvilli, decreased expressions of epithelial cell markers like Ecadherin and Z0-1, and increased expression of fibroblast markers (e.g. a-SMA). It also involves cytoskeleton re-modelling, intercellular matrix degradation and changes in adhesion between the cells and matrix, resulting in enhanced ability of cell migration and invasion [5] . Yanez-Mo et al [22] discovered that peritoneal mesothelial cells exhibited EMT shortly after PD, which manifested in loss of epithelial cell morphology, down-regulated expression of cytokeratin and E-cadherin, and up-regulated expression of a2 integrin. They also found that peritoneal mesothelial cells cultured in vitro in PD effluent showed many morphological changes, including epithelial cell-likeness, fibroblastlikeness and a mixture of both features.
The intercellular adhesion molecule-1 (ICAM-1) was highly expressed in these different forms of cells, suggesting that the fibroblast-like cells were derived from peritoneal mesothelial cells. A study of 35 patients treated with standard PD for 2 years, found that 74 % of them experienced mesothelial cell layer loss, 46 % experienced peritoneal fibrosis, and 17 % had evidence of in situ EMT [23] . Studies have shown that TGF-β1 mediates EMT through Smad pathway [17, 19] . The target gene regulating TGF-β1 in EMT is dependent on the transcriptional regulation of smad2 and smad3, while smad7 interdicts its combination with TGF-β type I receptor by inhibiting the phosphorylation of activated Smad protein [17, 19] .
Overexpression of TGF-β1 in rodents can cause EMT of peritoneal mesothelial cells [24] . This has been demonstrated by using adenovirus to introduce TGF-β1 into the peritoneum so as to overexpress TGF-β1, thereby inducing EMT of HPMCs and peritoneal fibrosis [25] . Bone morphogenetic protein reverses HPMC transition by inhibiting smad2/3 and MAPKs resulting from hyperglycemia-activated TGF-β1. In the present study, it was discovered that PDF significantly enhanced the expressions of mRNAs for TGF-β1 and smad2, and suppressed the mRNA expression of smad7. However, the addition of T-II A led to significant down-regulation of the expression of mRNAs for TGF-β1 and smad2, and significant up-regulation of the expression of smad7 mRNA. This clearly suggests that T-II A inhibits the TGF-β1 signal transduction pathway; and by implication, it also inhibits EMT. The results of this study indicate that TGF-β1/smad3 signaling transduction pathway plays an important role in EMT during peritoneal fibrosis, and that T-II A has promising potential as an effective drug for the prevention of tissue fibrosis.
CONCLUSION
T-IIA treatment inhibits EMT of HPMCs via regulation of TGF-β/smad pathway, thereby preventing PD-induced peritoneal fibrosis. Thus T-IIA offers tremendous potential for the development of a new drug for the treatment of PD-linked peritoneal fibrosis.
